Scientists have assembled the most extensive map to date of gene activity in the human prefrontal cortex, a brain region that underlies planning, decision‑making and emotional regulation. The effort catalogued RNA expression in more than 6.3 million individual cells drawn from nearly 1,500 donors, providing a population‑scale resource for studying neurodegenerative and psychiatric illnesses.
Scale and Scope of the Study
The project, coordinated by the PsychAD Consortium—a National Institutes of Health‑funded partnership of U.S. institutions—began in 2019 with the aim of linking genetic variation, ageing and disease to cellular changes in the brain. Researchers focused on the dorsolateral prefrontal cortex because of its pivotal role in working memory and executive function, processes that guide planning, focus and multitasking. Disruption of this subregion is associated with several psychiatric disorders and forms of dementia.
Donor tissue spanned the full human lifespan, from infants to a 108‑year‑old individual, and represented diverse ancestries. The cohort included neurotypical controls as well as individuals diagnosed with one of eight brain disorders: Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, vascular dementia, tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder.
Using single‑cell RNA sequencing, the team captured the transcriptome of each cell at the moment of sampling, delivering a granular view of cellular status and function. The resulting dataset comprises gene‑activity profiles for neurons, immune cells and vascular cells, enabling direct comparison across disease states and healthy aging.
Implications for Brain Disease Research
Analysis of healthy brains revealed three distinct phases of dorsolateral prefrontal cortex development. The first phase, occurring in early life, is characterized by rapid remodeling of gene expression. A second, more stable period begins around age 24 and persists through mid‑life. A third remodeling phase emerges near age 65, marked by altered activity in cell types linked to immune responses, stress pathways and circadian regulation.
“Studying the same region under different conditions enables more consistent comparisons and helps connect our results to existing genetic and molecular studies,” said Panos Roussos, director of the Center for Disease Neurogenomics at Icahn School of Medicine at Mount Sinai and co‑author on all eight papers describing the work. He added that while the prefrontal cortex offers a crucial window into brain disease, additional brain regions will be needed to complete the picture.
External experts praised the project’s breadth. Zhichao Miao, a computational biologist at the Guangzhou National Laboratory in China, noted that previous single‑cell brain studies were limited to small numbers of individuals, and that moving to a population‑scale dataset expands the range of questions that can be addressed.
The comprehensive atlas is expected to accelerate research into the molecular mechanisms underlying Alzheimer’s disease and the other seven disorders represented in the cohort. By linking specific gene‑activity patterns to particular cell types and disease phenotypes, investigators can generate more precise hypotheses about disease pathways, identify potential therapeutic targets, and refine diagnostic biomarkers.
Future work will likely extend the mapping approach to additional brain regions and integrate the prefrontal cortex data with other omics modalities. Such efforts aim to construct a multidimensional reference of the human brain that can serve as a foundation for translational studies and ultimately improve clinical outcomes for patients suffering from neurodegenerative and psychiatric conditions.
Helene Elliott is the Lead Science & Space Reporter at News Raise. She reports on aerospace missions, astrophysics discoveries, quantum research, and environmental technology.
